Harvard Bioscience Formalizes CEO & CFO Employment Agreements, Incentivizes Refinancing

summarizeSummary

Harvard Bioscience formalized employment agreements for its CEO and appointed its interim CFO permanently, detailing new compensation packages and a performance bonus for the CEO tied to credit facility refinancing.

check_boxKey Events

• Formal CFO Appointment

  Mark Frost, previously Interim CFO, has been formally appointed as Chief Financial Officer and Treasurer, effective March 6, 2026.

• CEO Employment Agreement Updated

  John Duke's employment agreement was amended, setting his annual base salary at $515,000 and extending his term until July 16, 2027, with automatic two-year extensions.

• CFO Employment Agreement Updated

  Mark Frost's employment agreement was amended, setting his annual base salary at $375,000 and extending his term until April 10, 2027, with automatic two-year extensions.

• Refinancing Incentive for CEO

  CEO John Duke is eligible for a $100,000 cash bonus upon the successful refinancing of the company's credit facility, in lieu of his 2025 annual bonus.

auto_awesomeAnalysis

Harvard Bioscience has formalized employment agreements for its CEO, John Duke, and appointed Mark Frost as Chief Financial Officer, who previously served as Interim CFO. These agreements outline new compensation structures, including base salaries, annual cash incentives, and equity grants. Notably, CEO John Duke is eligible for a $100,000 cash bonus tied to the successful refinancing of the company's credit facility, a critical financial event for this micro-cap company. The formalization of these key executive roles and the performance-based incentive for refinancing provide a degree of stability and strategic focus, especially as the company approaches a reverse stock split.